Guangdong-Hong Kong-Macao Joint Laboratory of Human-Machine Intelligence-Synergy Systems, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Biomolecules. 2022 Aug 21;12(8):1156. doi: 10.3390/biom12081156.
The outbreak of COVID-19 caused millions of deaths worldwide, and the number of total infections is still rising. It is necessary to identify some potentially effective drugs that can be used to prevent the development of severe symptoms, or even death for those infected. Fortunately, many efforts have been made and several effective drugs have been identified. The rapidly increasing amount of data is of great help for training an effective and specific deep learning model. In this study, we propose a multi-task deep learning model for the purpose of screening commercially available and effective inhibitors against SARS-CoV-2. First, we pretrained a model on several heterogenous protein-ligand interaction datasets. The model achieved competitive results on some benchmark datasets. Next, a coronavirus-specific dataset was collected and used to fine-tune the model. Then, the fine-tuned model was used to select commercially available drugs against SARS-CoV-2 protein targets. Overall, twenty compounds were listed as potential inhibitors. We further explored the model interpretability and exhibited the predicted important binding sites. Based on this prediction, molecular docking was also performed to visualize the binding modes of the selected inhibitors.
新型冠状病毒肺炎(COVID-19)疫情在全球范围内已导致数百万人死亡,总感染人数仍在不断上升。有必要确定一些潜在有效的药物,以预防感染者出现严重症状,甚至死亡。幸运的是,目前已做了许多努力,并已确定了几种有效的药物。不断增加的大量数据对训练有效的、特定的深度学习模型非常有帮助。在本研究中,我们提出了一种多任务深度学习模型,用于筛选针对 SARS-CoV-2 的市售有效抑制剂。首先,我们在几个异构的蛋白质-配体相互作用数据集上对模型进行了预训练。该模型在一些基准数据集上取得了有竞争力的结果。接下来,我们收集了一个专门针对冠状病毒的数据集,并用于对模型进行微调。然后,我们使用经过微调的模型来筛选针对 SARS-CoV-2 蛋白靶标的市售药物。总体而言,列出了二十种化合物作为潜在的抑制剂。我们进一步探索了模型的可解释性,并展示了预测的重要结合位点。基于此预测,还进行了分子对接以可视化所选抑制剂的结合模式。